Gonococcal Isolate Surveillance Project (GISP)

Slides:



Advertisements
Similar presentations
Update on Gonococcal Resistance in the United States Susan A. Wang, MD, MPH Division of STD Prevention National Center for HIV, STD, and TB Prevention.
Advertisements

Kingdom of Bahrain Ministry of Health ( Syndromic Mangement ) Adopted from : IPPF MEDICAL AND SERVICE DELIVERY GUIDELINES FOR SEXUAL AND REPRODUCTIVE HEALTH.
Antimicrobial Resistance in N. gonorrhoeae – An Overview 2014 INTRODUCTION Progressive antimicrobial resistance in Neisseria gonorrhoeae is an emerging.
Recent Trends in Gonorrhea in the United States Lori M. Newman, MD Division of STD Prevention CDC Jacksonville, FL May 9, 2006.
Alternative Cephalosporin Treatment Options for Gonorrhea Christopher S. Hall, MD, MS 1 Michael Samuel, DrPH, 1 Michael McElroy, MPH, 1 Jessica Frasure,
Antimicrobial Resistance in N. gonorrhoeae: In Brief 2014 INTRODUCTION Increased action is needed to help prevent and control gonorrhea. Worldwide antimicrobial.
Challenges to IPP: Emerging Gonococcal Antimicrobial Resistance and Skepticism That Screening in Its Current Form Can Reduce Chlamydial Morbidity Edward.
STD Surveillance 2001 Adapted from CDC by Jill Gallin, CPNP Assistant Professor of Clinical Nursing.
2014 PATIENT HISTORY How would you diagnose and screen Miranda? How would you treat Miranda? Are there any additional steps you would take? Antimicrobial.
Gonococcal Isolate Surveillance Project (GISP)
Gonorrhea Sexually Transmitted Disease Surveillance 2000 Division of STD Prevention.
Neisseria gonorrhoeae
Gonorrhea Sexually Transmitted Disease Surveillance 2007 Division of STD Prevention.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 94 Drug Therapy of Sexually Transmitted Diseases.
Gonorrhea Sexually Transmitted Disease Surveillance 2008 Division of STD Prevention.
Sexually Transmitted Disease Surveillance 2011 Division of STD Prevention.
Sexually Transmitted Disease Surveillance 2013 Division of STD Prevention.
Denver Prevention Training Center Denver Public Health Department Pieces of the Puzzle Conference Great Falls November 21, 2013.
All Slides Sexually Transmitted Disease Surveillance 2000 Division of STD Prevention.
Infertility Prevention Project Region I June 1, 2009 Wells Beach, Maine Infertility Prevention Project Region I June 1, 2009 Wells Beach, Maine Steven.
Application of an Epi Profile: Gonorrhea in the U.S. Region V Gonorrhea Control Meeting.
Is Gonorrhoea untreatable?
Trevor Winstanley Rebecca Clarke Department of Microbiology
Gonorrhea in New York City Epidemiology, Disease Control Activities, and Challenges Presented by: Julia A. Schillinger, MD, MSc CAPT USPHS Bureau of STD.
Gonorrhea Epidemiology and Control Efforts in Louisiana Lisa Longfellow, MPH October 14, 2009.
Sexually Transmitted Disease (STD) Surveillance Report, 2009 Minnesota Department of Health STD Surveillance System Minnesota Department of Health STD.
Faiza Ali MD, Ericka Hayes MD, Gaurav Kaushik MPH, Nicole Carr RN, Katie Plax MD Washington University School Of Medicine Department of Pediatrics.
All Slides Sexually Transmitted Disease Surveillance 1998 Division of STD Prevention.
Richard Lechtenberg, MPH University of California, Berkeley California Dept. of Public Health Enough to Make You CRiNGe: Variation in Adherence to the.
Rapid Emergence of Gonococcal Fluoroquinolone Resistance in Men Who Have Sex with Men in King County, WA WLH Whittington MR Golden KK Winterscheid SA Wang.
Antibiotic resistance in Neisseria gonorrhoeae Karen Cloud-Hansen, PhD March 12, 2007.
Laboratory Issues in STD Testing From the Perspective of The Bureau of STD Control Jennifer Baumgartner, MSPH Preeti Pathela, DrPH Julia Schillinger, MD,
All Slides Sexually Transmitted Disease Surveillance 2006 Division of STD Prevention.
Sexually Transmitted Disease (STD) Surveillance Report, 2007 Minnesota Department of Health STD Surveillance System Minnesota Department of Health STD.
Gonorrhea Sexually Transmitted Disease Surveillance 1998 Division of STD Prevention.
Chlamydia Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.
All Slides Sexually Transmitted Disease Surveillance 2002 Division of STD Prevention.
GONORRHEA Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention.
South Dakota STD Update Webinar – August 15, 2012 Kees Rietmeijer, MD, PhD Medical Director, Denver STD/HIV Prevention Training Center.
All Slides Sexually Transmitted Disease Surveillance 2001 Division of STD Prevention.
North Dakota STD Update Webinar – August 23, 2012 Kees Rietmeijer, MD, PhD Medical Director, Denver STD/HIV Prevention Training Center.
Sexually Transmitted Disease Surveillance 2013 Division of STD Prevention.
All Slides Sexually Transmitted Disease Surveillance 1999 Division of STD Prevention.
Chlamydia Sexually Transmitted Disease Surveillance 2004 Division of STD Prevention.
All Slides Sexually Transmitted Disease Surveillance 2008 Division of STD Prevention.
Gonorrhea Sexually Transmitted Disease Surveillance 2006 Division of STD Prevention.
22 February 2016 GRASP (Gonococcal Resistance to Antimicrobials Surveillance Programme) Catherine Ison Sexually Transmitted Bacteria Reference Laboratory.
Antimicrobial Resistance Surveillance (AMR Surveillance)
All Slides Sexually Transmitted Disease Surveillance 2005 Division of STD Prevention.
GONORRHEA Sexually Transmitted Disease Surveillance 2010 Division of STD Prevention.
Gonorrhea Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.
Drug Therapy of Sexually Transmitted Diseases. Sexually Transmitted Diseases  Sexually transmitted diseases (STDs)  Infections or parasitic diseases.
Monitoring Emerging Resistance in Neisseria gonorrhoeae in the United States Eileen L. Yee, MD 2008 National STD Prevention Conference March 11, 2008 Chicago,
100% Ciprofloxacin resistance in gonococcal isolates in patients with or at high risk of HIV acquisition in an urban Ugandan clinic DR EMILY MABONGA KING’S.
SEXUALLY TRANSIMITTED DISEASES BY
Topic Gonorrhea Diseases
Gonorrhoea & PID PHCP 402 By K S Labaran.
Lizzi Torrone, MSPH, PhD Lead, Surveillance & Special Studies Team
Sexually Transmitted Disease Surveillance 2009
Chlamydial and Gonococcal Infections
Non-Viral STD of Major significance
Current STD Testing and Treatment Guidelines
Gonorrhea Epidemiology and Control Efforts in Louisiana
Gonorrhea Sexually Transmitted Disease Surveillance 2010
A decade of multi-drug resistant N. gonorrhoea in Coventry, UK
Neisseria gonorrhoeae: the first untreatable infection
Gonorrhoea antimicrobial resistance in Ireland, 2010 – 2017 On behalf of the National Forum on Antimicrobial Resistance in Neisseria gonorrhoeae Health.
Management of Gonorrhea and Chlamydia in Patients with HIV
By Abhi ,Jenny, Akanksha, Sanat, Sriya, Sushmitha, Mariam,Digveer,
MSM Attending STD Clinics HIV Testing More Frequently: Implications for HIV Prevention and Surveillance D Helms1, H Weinstock1, K Mahle1, A Shahkolahi1,2,
Presentation transcript:

Gonococcal Isolate Surveillance Project (GISP) Neisseria Gonorrhoeae (GC) culture specimen streaking

Neisseria gonorrhoeae Gonorrhea is a bacterial STD Sequelae of untreated infection include Pelvic inflammatory disease Infertility Chronic pelvic pain Increases risk of HIV transmission and acquisition Gonorrhea is second most frequently reported communicable disease in the U.S.

Gonococcal Resistance to Antimicrobial Agents 1970’s – penicillin- and tetracycline- resistant N. gonorrhoeae appeared, leading to abandonment of these therapies for gonorrhea 1990’s to present – prevalence of fluoroquinolone resistant N. gonorrhoeae (QRNG) has been increasing 2000 - CDC recommends that fluoroquinolones (FQs) no longer be used to treat gonorrhea acquired in Hawaii, Pacific Islands, or Asia; need travel history for all GC patients

Gonoccocal Resistance to Antimicrobial Agents (continued) 2002 - CDC recommends that use of FQs in California and in other areas with increased QRNG may be inadvisable 2004 – Due to increases in QRNG, CDC recommends that FQs no longer be used to treat gonorrhea Current CDC recommended primary therapies for GC are: Cefixime, Ceftriaxone, Ciprofloxacin, Ofloxacin, Levofloxacin PLUS, IF CHLAMYDIAL INFECTION IS NOT RULED OUT Azithromycin OR Doxycycline

The Gonococcal Isolate Surveillance Project (GISP) Increasing rates of gonorrhea and ciprofloxacin resistance pose challenges to disease control. GISP is the national sentinel surveillance system established in 1986 by CDC. Consists of public STD clinics in 30 US cities and 5 regional labs. 25 male gonococcal isolates tested from each site each month. The LA Sentinel Site was established in 2003. It includes 2 high-volume STD clinics with diverse populations, South Health Center and the Los Angeles Gay and Lesbian Center (LAGLC). The Gonoccocal Isolate Surveillance Project (GISP) is an example of how increased surveillance by clinics and labs can impact disease treatment.

Establishing LA as a GISP Site In mid-March 2003, the two STD clinics began collecting urethral cultures from males presenting with expressible urethral discharge characteristic of gonorrhea. Clinics collected demographic, clinical, and client-reported behavioral data. Gonococcal isolates presumptively identified by the LA County Public Health Lab were shipped to the Denver GISP Regional Lab for confirmation and antibiotic susceptibility testing by agar dilution.

GISP — Location of participating clinics and regional laboratories: United States, 2004 Adapted from CDC slides

GISP Percent of Neisseria gonorrhoeae isolates with resistance to ciprofloxacin by sexual behavior, 2001–2004 Adapted from CDC slides

GISP Penicillin and tetracycline resistance among GISP isolates, 2004 Note: PPNG=penicillinase-producing N. gonorrhoeae; TRNG=plasmid-mediated tetracycline-resistant N. gonorrhoeae; PPNG-TRNG=plasmid-mediated penicillin- and tetracycline-resistant N. gonorrhoeae; PenR=chromosomally mediated penicillin resistant N. gonorrhoeae; TetR=chromosomally mediated tetracycline-resistant N. gonorrhoeae; CMRNG=chromosomally mediated penicillin- and tetracycline-resistant N. gonorrhoeae. Adapted from CDC slides

GISP - Percent of Neisseria gonorrhoeae isolates with resistance or intermediate resistance to ciprofloxacin, 1990–2004 Note: Resistant isolates have ciprofloxacin MICs ≥ 1 µg/ml. Isolates with intermediate resistance have ciprofloxacin MICs of 0.125 - 0.5 µg/ml. Susceptibility to ciprofloxacin was first measured in GISP in 1990. Adapted from CDC slides

LA GISP Isolates by Clinic March 2003 – June 2005

Race/Ethnicity of GISP Participants March 2003 – June 2005 N=572

Sexual Orientation of GISP Participants March 2003 – June 2005 Overall, the majority of the gonorrhea positive men were heterosexual (62%). However, when separated by clinic, 96% of men from South Health Center were heterosexual, while 97% of men from LAGLC were either homosexual or bisexual. N=572

Number of Isolates

HIV Status, Positive Cultures and Resistant Isolates Number of Isolates

Resistance and Decreased Antimicrobial Susceptibility Number of Isolates N=572

L.A. GISP Project Total 21% reported non-injection drug use 7% used antibiotics 7% traveled outside CA 1% reported injection drug use 1% was involved in sex work During the 60 days prior to diagnosis of gonorrhea, GISP patients reported the following behaviors.

L.A. GISP TREATMENT FOR GC AND CHL Primary treatment for gonorrhea: Ceftriaxone 250 mg (93%) Primary treatment for chlamydia: Azithromycin 1 g (98%) The antimicrobial agents given to GISP participants are shown here.

Ciprofloxacin-Resistant GC in California Prevalence of cipro-resistant GC in CA >10% in 2002 CA GC Tx Recommendations: Avoid the use of fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin) to treat GC in California. Use ceftriaxone 125mg by intramuscular (IM) injection to treat uncomplicated gonococcal infections of the cervix, urethra, and rectum Fluoroquinolones (Cipro) are no longer recommended by the CDC as treatment for GC in CA as of 2002.

The Problem with QRNG Limited availability of a recommended oral treatment regimen for gonorrhea poses practical problems for treating QRNG. Besides the fluoroquinolones, cefixime, whose manufacture was discontinued in 2002, is the only CDC-recommended oral agent for treating gonorrhea. The health departments of California and Washington state have suggested alternative oral treatments (e.g., cefpodoxime 400 mg) that have not yet been evaluated adequately. Cipro was orally administered. The only other oral single dose tx was cefixime, but its production was discontinued in 2002. No other single dose oral antimicrobial regimen meets efficacy and safety criteria. Ceftriaxone 125 mg IM (intramuscular) single dose is the current recommended tx in CA. Cefpodoxime is being researched as an oral alternative for GC tx.

The Challenges of Monitoring Gonococcal Resistance Few labs perform susceptibility testing. Mainly public health labs, yet >60% GC reported from private sector. Absence of culture testing, so no organisms for susceptibility testing. Non-culture tests (amplified tests) rapidly replacing culture. Some health depts no longer have GC culture capacity at all.

The Challenges of Monitoring Gonococcal Resistance (continued) Bias toward over-representation of data from rectal and pharyngeal sources. Culture is the preferred test for these anatomic sites (other tests not recommended). Less data from urethral and endocervical sites due to increased Nucleic Acid Amplification Test usage. Limited sampling of certain populations: military, women, private patients

More Information Clinical Lab Survey Report, 2002 GISP http://www.lapublichealth.org/std/ The "Reports" section contains this and other reports published by the LA County STD Program. GISP http://www.cdc.gov/std/gisp/ Resource website for information on antimicrobial resistant Neisseria gonorrhoeae.